

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM391946

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Kinemed, Inc.		05/31/2016	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Kinemed DIP Lenders, LLC		
<b>Street Address:</b>	5260 North Palm Avenue		
<b>Internal Address:</b>	Suite 201		
<b>City:</b>	Fresno		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	93704		
<b>Entity Type:</b>	Limited Liability Company: CALIFORNIA		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3230475	KINEMED	
<b>Registration Number:</b>	3230474	KINEMED	
<b>Registration Number:</b>	3395688	KINEMED	
<b>Registration Number:</b>	3291448	AQUATAG	
<b>Registration Number:</b>	3280370	KINEMARKER	
<b>Registration Number:</b>	3234122	KINEMED	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6613260418		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	661-395-1000		
<b>Email:</b>	JDuncan@kleinlaw.com		
<b>Correspondent Name:</b>	James M. Duncan		
<b>Address Line 1:</b>	P.O. Box 11172		
<b>Address Line 4:</b>	Bakersfield, CALIFORNIA 93389		
<b>NAME OF SUBMITTER:</b>	James M. Duncan		
<b>SIGNATURE:</b>	/James M. Duncan/		
<b>DATE SIGNED:</b>	07/19/2016		

OP \$165.00 3230475

**Total Attachments: 27**

source=Fully Executed DIP Security Agreement (2)#page1.tif

source=Fully Executed DIP Security Agreement (2)#page2.tif

source=Fully Executed DIP Security Agreement (2)#page3.tif

source=Fully Executed DIP Security Agreement (2)#page4.tif

source=Fully Executed DIP Security Agreement (2)#page5.tif

source=Fully Executed DIP Security Agreement (2)#page6.tif

source=Fully Executed DIP Security Agreement (2)#page7.tif

source=Fully Executed DIP Security Agreement (2)#page8.tif

source=Fully Executed DIP Security Agreement (2)#page9.tif

source=Fully Executed DIP Security Agreement (2)#page10.tif

source=Fully Executed DIP Security Agreement (2)#page11.tif

source=Fully Executed DIP Security Agreement (2)#page12.tif

source=Fully Executed DIP Security Agreement (2)#page13.tif

source=Fully Executed DIP Security Agreement (2)#page14.tif

source=Fully Executed DIP Security Agreement (2)#page15.tif

source=Fully Executed DIP Security Agreement (2)#page16.tif

source=Fully Executed DIP Security Agreement (2)#page17.tif

source=Fully Executed DIP Security Agreement (2)#page18.tif

source=Fully Executed DIP Security Agreement (2)#page19.tif

source=Fully Executed DIP Security Agreement (2)#page20.tif

source=Fully Executed DIP Security Agreement (2)#page21.tif

source=Fully Executed DIP Security Agreement (2)#page22.tif

source=Fully Executed DIP Security Agreement (2)#page23.tif

source=Fully Executed DIP Security Agreement (2)#page24.tif

source=Fully Executed DIP Security Agreement (2)#page25.tif

source=Fully Executed DIP Security Agreement (2)#page26.tif

source=Fully Executed DIP Security Agreement (2)#page27.tif

## DEBTOR IN POSSESSION SECURITY AGREEMENT

This Security Agreement ("Agreement") dated as of May \_\_\_, 2016, is entered into by and between KINEMED, INC., a Delaware corporation and the debtor in possession in the Chapter 11 Case (defined below) (the "Borrower"), and KINEMED DIP LENDERS, LLC, a California limited liability company (the "Secured Party").

### RECITALS

A. Borrower and Secured Party have entered into a Loan Agreement dated of even date herewith (the "Credit Agreement"). Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Credit Agreement.

B. It is a condition to the Secured Party's agreement to advance loans under the Credit Agreement that Borrower grant to Secured Party a perfected security interest in substantially all of its assets as security for the payment and performance of all of Borrower's obligations ("Obligations") under and as defined in the Credit Agreement and all of the other Loan Documents (as defined in the Credit Agreement).

### AGREEMENT

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and conditions herein, the parties hereby agree as follows:

1. Grant of Security. As security for and in further consideration for the obligations of Borrower to pay to Secured Party the Obligations, and as security for Borrower's obligations under this Agreement, Borrower hereby grants to Secured Party a security interest in all present and future right, title and interest of Borrower in or to the following assets (certain of the capitalized terms in this Section 1 are defined in Exhibit "A" hereto):

(a) all personal property and assets of Borrower, including without limitation, all of Borrower's right, title and interest in and to the following property, whether now owned or hereafter acquired and wherever located: (a) all Accounts; (b) all Deposit Accounts; (c) all Equipment; (d) all Fixtures; (e) all General Intangibles; (f) all Receivables; (g) all Inventory; (h) all Rights to Payment; (i) all Investment Property and securities; (j) all Software; and (k) all other Goods and personal property of Borrower, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located;

(b) Any and all choses in action, causes of action, claims and entitlements, now existing or hereafter arising, including Commercial Tort Claims, other than Avoidance Claims;

(c) Any and all claims, rights and interests in any of the above and all substitutions for, additions and accessions to any of the above; and

(d) Any and all Intellectual Property, including, but not limited to, that set forth on Exhibit B; and

(e) Any and all Proceeds and products of each and all of the above.

2. The property so described in Section 1 shall be referred to hereafter collectively as the "Collateral". The Collateral secures and will secure Borrower's Obligations.

3. Perfection of Security Interest. The liens and security interests in the Collateral created herein shall be deemed automatically perfected upon entry of the of the orders of the Bankruptcy Court approving the Obligations under and as defined in the Credit Agreement and all of the other Loan Documents, and Secured Party may, but shall not be required to, file or record any documents or take any further steps in order to perfect such liens and security interests. Borrower agrees to execute and deliver to Secured Party, and hereby authorizes Secured Party to prepare and file, all financing statements (including an "all assets" filing), deeds of trust, assignments of rents, notices, account control agreements, abstracts of lien, and other documents from time to time reasonably requested by Secured Party to maintain a perfected security interest in the Collateral in favor of Secured Party; perform such other acts, and execute and deliver to Secured Party such additional conveyances, assignments, agreements and instruments, as Secured Party may at any time reasonably request in connection with the administration and enforcement of this Agreement or Secured Party's rights, powers and remedies hereunder.

4. Representations, Warranties and Covenants. Borrower hereby represents, warrants and covenants that, unless compliance is waived by Secured Party in writing:

(a) Borrower will notify Secured Party in writing prior to any change in Borrower's place of business, or, if Borrower has or acquires more than one place of business, prior to any change in Borrower's chief executive office, the office or offices where Borrower's books and records concerning the Collateral are kept, or where Borrower's inventory is kept;

(b) Borrower will immediately notify Secured Party of any proposed or actual change of Borrower's name, identity, jurisdiction of organization, or corporate structure;

(c) Borrower will not sell, lease, contract for sale or lease, convey or otherwise dispose of any of the Collateral, except for fair consideration and in the ordinary course of Borrower's business or pursuant to an order of the Bankruptcy Court under Section 363(b) of the Bankruptcy Code;

(d) Borrower will promptly notify Secured Party in writing of any event which affects the value of the Collateral in a material way, the ability of Secured Party to dispose of the Collateral, or the rights and remedies of Secured Party in relation thereto, including, but not limited to, the levy of any legal process against the Collateral, and the entry of any order affecting the Collateral. Upon reasonable prior notice at reasonable times during normal business hours, Borrower hereby authorizes Secured Party's officers, employees, representatives and agents to inspect the Collateral and to discuss the Collateral and the Records relating thereto with Borrower's officers, and, in the case of any Right to Payment, with any Person which is or may be obligated thereon; and

(e) Borrower will diligently collect all receivables and keep accurate books and records of the receivables and all collections thereof.

5. Defaults. Any one or more of the following shall be an "Event of Default" hereunder:

(a) Subject to the notice and cure rights of Borrower, if any, under the Credit Agreement, Borrower shall fail to pay any of the Obligations in accordance with their terms;

(b) Borrower shall default on any of its Obligations under any Loan Document, including without limitation, the Credit Agreement; or

(c) Borrower shall materially breach any term or provision of this Agreement.

6. Remedies. Upon the occurrence of an Event of Default, Secured Party may do any one or more of the following, subject to all provisions of the Credit Agreement and the automatic stay of Section 362(a) of the Bankruptcy Code and any other constraints or limitations set forth in other Loan Documents:

(a) Declare all Obligations to be immediately due and payable;

(b) Enforce the security interest given hereunder pursuant to the UCC or any other law or court order, and enforce any and all other rights and remedies of Secured Party under the DIP Loan Order, the Credit Agreement, this Agreement or any of the other Loan Documents;

(c) Require Borrower to assemble the Collateral and the records pertaining to the Collateral and make them available to Secured Party at a place designated by Secured Party;

(d) Enter any premises of Borrower and take possession of the Collateral and of the records pertaining to the Collateral;

(e) Grant extensions, compromise claims and sell the Collateral for less than face value;

(f) Use, in connection with any assembly or disposition of the Collateral, any trademark, trade name, trade style, copyright, patent right or technical process used or utilized by Borrower;

(g) Proceed in the foreclosure of Secured Party's security interest and sale of the Collateral in any manner permitted by law, the Interim Order, the Final Order, any other court order or this Agreement; and

(h) Sell, lease or otherwise dispose of the Collateral at public or private sale. To the extent permitted by law, Borrower hereby specifically waives all rights of redemption and any rights of stay or appraisal which it has or may have under any applicable law in effect from time to time. Any such public or private sales shall be held at such times and at such place(s) as Secured Party may determine, and may be adjourned or continued from time to time with or without notice. In case of the sale of all or any part of the Collateral on credit or for future delivery, the Collateral so sold may be retained by Secured Party until the selling price is paid by the purchaser, but Secured Party shall not incur any liability in case of the failure of such purchaser to pay for the Collateral and, in case of any such failure, such Collateral may be resold. Secured Party may, instead of exercising its power of sale, proceed to enforce its security interest in the Collateral by seeking a judgment or decree of a court of competent jurisdiction.

Nothing herein shall be construed to require Secured Party to pursue, or exhaust its remedies with respect to, the Collateral prior to proceeding directly against Borrower, or to prohibit Secured Party from seeking a deficiency judgment against Borrower.

7. Additional Covenants. Subject to the automatic stay of Section 362(a) of the Code, Borrower hereby agrees that, in addition to the provisions of Section 6, Secured Party may, in compliance with the Credit Agreement, at any time and its option do any one or more of the following, and Borrower hereby agrees to promptly comply with any of the following:

(a) Require Borrower to segregate all collections and proceeds of the Collateral so that they are capable of identification, and deliver daily such collections and proceeds to Secured Party in kind;

(b) Require Borrower to periodically deliver to Secured Party records and schedules which show the status and condition of the Collateral, where it is located and such contracts or other matters which affect the Collateral;

(c) Verify the Collateral and inspect the books and records of Borrower and make copies thereof or extracts therefrom;

(d) Require Borrower to deliver to Secured Party any receivables evidenced by instruments or chattel paper;

(e) Require Borrower to obtain Secured Party's prior written consent to any sale, lease, contract of sale or lease, or other disposition of any inventory or

of any products, or any other goods covered by any document of title (except for sales of inventory in the ordinary course of business prior to the occurrence of an Event of Default);

(f) Notify any account Borrowers, any buyers of the Collateral or any other persons of Secured Party's interest in the Collateral and the proceeds thereof;

(g) Require Borrower to direct all account Borrowers to forward all remittances, payments and proceeds of the Collateral to a post office box under Secured Party's exclusive control; and

(h) Demand and collect any receivables and any proceeds of the Collateral. In connection therewith, Borrower irrevocably authorizes Secured Party to endorse or sign Borrower's name on all collections, receipts or other documents, take possession of and open the mail addressed to Borrower and remove therefrom payments of receivables and proceeds of the Collateral.

8. Miscellaneous.

(a) If any provision of this Agreement is inoperative or unenforceable for any reason, such circumstances shall not have the effect of rendering the provision in question inoperative or unenforceable in any other case or circumstance, or of rendering any other provision or provisions herein contained invalid, inoperative, or unenforceable to any extent whatsoever.

(b) All notices, requests, demands, approvals, consents, waivers and other communications required or permitted to be given under this Agreement shall be directed and received as set forth in the Credit Agreement.

(c) The headings contained in this Agreement are for purposes of convenience only and shall not affect the meaning or interpretation of this Agreement.

(d) This Agreement, together with the other Loan Documents, constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof.

(e) This Agreement may be executed (including by facsimile or electronic mail transmission) with counterpart signature pages or in several counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument.

(f) THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING AS TO VALIDITY, INTERPRETATION AND EFFECT, BY THE INTERNAL LAWS OF THE STATE OF CALIFORNIA WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS RULES

THEREOF. EACH OF SECURED PARTY AND BORROWER AGREE THAT ANY AND ALL ACTIONS TO INTERPRET OR ENFORCE THE PROVISIONS OF THIS AGREEMENT AND ANY OTHER DOCUMENTS REFERRED TO IN THIS AGREEMENT SHALL BE BROUGHT IN THE BANKRUPTCY COURT (AS DEFINED IN THE CREDIT AGREEMENT). EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE BANKRUPTCY COURT, AND IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR THE INTERPRETATION OR ENFORCEMENT OF THIS AGREEMENT OR SUCH OTHER DOCUMENT THAT IT IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURT OR THAT THE VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS AGREEMENT OR ANY SUCH OTHER DOCUMENT MAY NOT BE ENFORCED IN OR BY SAID COURT. EACH OF BORROWER AND SECURED PARTY HEREBY CONSENTS TO AND GRANTS ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF ANY SUCH DISPUTE AND AGREES THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH ANY SUCH ACTION OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 8(b), OR IN SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE THEREOF.

(g) This Agreement shall not be assignable or otherwise transferable by Borrower or Secured Party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, including any chapter 7 or chapter 11 trustee as is appointed in Borrower's bankruptcy case.

(h) Nothing in this Agreement shall confer any rights upon any person other than the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.

(i) No discharge of this Agreement, and no waiver hereunder, shall be valid or binding unless set forth in writing and duly executed by the party against whom enforcement of the discharge or waiver is sought. Any such waiver shall constitute a waiver only with respect to the specific matter described in such writing and shall in no way impair the rights of the party granting such waiver in any other respect or at any other time. Neither the waiver by any of the parties hereto of a breach of or a default under any of the provisions of this Agreement, nor the failure by any of the parties, on one or more occasions, to enforce any of the provisions of this Agreement or to exercise any right or privilege hereunder, shall be construed as a waiver of any other breach or default of a similar nature, or as a waiver of any of such provisions, rights or privileges hereunder. No amendment or modification of this Agreement shall be effective unless in a writing executed by all the parties hereto.




(j) Borrower shall, at its cost and expense, upon request of Secured Party, duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts as may be necessary or proper in the reasonable opinion of Secured Party to carry out more effectively the provisions and purposes of this Agreement and the other Loan Documents.

BORROWER:

KINEMED, INC., a Delaware corporation


By:

  
David M. Fineman, C.E.O.


SECURED PARTY:

KINEMED DIP LENDERS, LLC, a California limited liability company

By:

  
Manager

By:

  
Manager

## Exhibit "A"

### Collateral Definitions

**"Collateral"** means all personal property and assets of Borrower, including without limitation, all of Borrower's right, title and interest in and to the following property, whether now owned or hereafter acquired and wherever located: (a) all Accounts; (b) all Deposit Accounts; (c) all Equipment; (d) all Fixtures; (e) all General Intangibles; (f) all Receivables; (g) all Inventory; (h) all Rights to Payment; (i) all Investment Property and securities; (j) all Software; and (k) all other Goods and personal property of Borrower, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, including, any and all choses in action, causes of action, claims and entitlements, now existing or hereafter arising, including Commercial Tort Claims; any and all claims, rights and interests in any of the above and all substitutions for, additions and accessions to any of the above; and any and all Proceeds and products of each and all of the above.

Capitalized terms used in the definition of Collateral are defined as follows:

**"Account"** means any "account," as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and, in any event, shall include, without limitation, all accounts receivable, book debts and other forms of obligations (other than forms of obligations evidenced by Chattel Paper, Documents or Instruments) now owned or hereafter received or acquired by or belonging or owing to Borrower (including, without limitation, under any trade name, style or division thereof) whether arising out of goods sold or services rendered by Borrower or from any other transaction, whether or not the same involves the sale of goods or services by Borrower (including, without limitation, any such obligation that may be characterized as an account or contract right under the UCC) and all of Borrower's rights in, to and under all purchase orders or receipts now owned or hereafter acquired by it for goods or services, and all of Borrower's rights to any goods represented by any of the foregoing (including, without limitation, unpaid seller's rights of rescission, replevin, reclamation and stoppage in transit and rights to returned, reclaimed or repossessed goods), and all monies due or to become due to Borrower under all purchase orders and contracts for the sale of goods or the performance of services or both by Borrower or in connection with any other transaction (whether or not yet earned by performance on the part of Borrower), now in existence or hereafter occurring, including, without limitation, the right to receive the proceeds of said purchase orders and contracts, and all collateral security and guarantees of any kind given by any person with respect to any of the foregoing.

**"Bankruptcy Court"** means the United States Bankruptcy Court for the Northern District of California, Oakland Division, or other court of competent jurisdiction.

**“Chattel Paper”** means any “chattel paper,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Commercial Tort Claims”** means any “commercial tort claim,” as such term is defined in the UCC, now or hereafter arising or acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Copyright License”** means any written agreement granting any right to use any Copyright or Copyright registration now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Copyrights”** means all of the following now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (i) all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; (ii) all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, any State thereof or any other country; (iii) all continuations, renewals or extensions thereof; and (iv) any registrations to be issued under any pending applications.

**“Credit Agreement”** is defined in Recital A of this Agreement.

**“Deposit Accounts”** means any “deposit accounts,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Documents”** means any “documents,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Equipment”** means any “equipment,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and any and all additions, substitutions and replacements of any of the foregoing, wherever located, together with all attachments, components, parts, equipment and accessories installed thereon or affixed thereto.

**“Financial Assets”** has the meaning given it in the UCC.

**“Fixtures”** means any “fixtures,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“General Intangibles”** means any “general intangibles,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and, in any event, shall include, without limitation, all right, title and interest that Borrower may now or hereafter have in or under any contract, interests in partnerships, joint ventures and other business associations, permits, goodwill, claims in or under insurance policies, including unearned premiums,

uncertificated securities, money, cash or cash equivalents, deposit, checking and other bank accounts, rights to receive tax refunds and other payments and rights of indemnification.

**“Goods”** means any “goods,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Instruments”** means any “instrument,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Intellectual Property”** means all Copyrights, Trademarks, Patents, Licenses, trade secrets, source codes, customer lists, proprietary or confidential information, inventions (whether or not patented or patentable), technical information, procedures, designs, knowledge, know-how, software, data bases, skill, expertise, experience, processes, models, drawings, materials, records and goodwill associated with the foregoing.

**“Inventory”** means any “inventory,” as such term is defined in the UCC, wherever located, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, and, in any event, shall include, without limitation, all inventory, goods and other personal property that are held by or on behalf of Borrower for sale or lease or are furnished or are to be furnished under a contract of service or that constitute raw materials, work in process or materials used or consumed or to be used or consumed in Borrower’s business, or the processing, packaging, promotion, delivery or shipping of the same, and all finished goods, whether or not the same is in transit or in the constructive, actual or exclusive possession of Borrower or is held by others for Borrower’s account, including, without limitation, all goods covered by purchase orders and contracts with suppliers and all goods billed and held by suppliers and all such property first may be in the possession or custody of any carriers, forwarding agents, truckers, warehousemen, vendors, selling agents or other Persons.

**“Investment Property”** means any “investment property,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Letter of Credit Rights”** means any “letter of credit rights,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, including any right to payment under any letter of credit.

**“License”** means any Copyright License, Patent License, Trademark License or other license of rights or interests now held or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and any renewals or extensions thereof.

**“Lien”** means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction.

**“Obligations”** means with respect to each Borrower, all debts, obligations and liabilities of such Borrower to Secured Party arising under the Credit Agreement or hereafter made, incurred or created under, pursuant to or in connection with the Credit Agreement or any other Loan Document (as defined in the Credit Agreement) whether voluntary or involuntary and however arising or evidenced, whether direct or acquired by Secured Party by assignment or succession, whether due or not due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and whether such Borrower may be liable individually or jointly, or whether recovery upon such debt may be or become barred by any statute of limitations or otherwise unenforceable; and all renewals, extensions and modifications thereof; and all attorneys' fees and costs incurred by Secured Party in connection with the collection and enforcement thereof as provided for in any Loan Document.

**“Patent License”** means any written agreement granting any right with respect to any invention on which a Patent is in existence now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Patents”** means all of the following property now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (a) all letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; (b) all reissues, continuations, continuations-in-part or extensions thereof; (c) all petty patents, divisionals, and patents of addition; and (d) all patents to be issued under any such applications.

**“Proceeds”** means “proceeds,” as such term is defined in the UCC and, in any event, shall include, without limitation, (a) any and all Accounts, Chattel Paper, Instruments, cash or other forms of money or currency or other proceeds payable to Borrower from time to time in respect of the Collateral, (b) any and all proceeds of any insurance, indemnity, warranty or guaranty payable to Borrower from time to time with respect to any of the Collateral, (c) any and all payments (in any form whatsoever) made or due and payable to Borrower from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any governmental authority (or any Person acting under color of governmental authority), and (d) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral.

**“Receivables”** means all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, and letters of credit and Letter of Credit Rights.

**“Records”** means all Borrower’s computer programs, software, hardware, source codes and data processing information, all written documents, books, invoices, ledger sheets, financial information and statements, and all other writings concerning Borrower’s business.

**“Rights to Payment”** means all Borrower’s accounts, instruments, contract rights, documents, chattel paper and all other rights to payment, including, without limitation, the Accounts, all negotiable certificates of deposit and all rights to payment under any Patent License, any Trademark License, any contract or any commercial or standby letter of credit.

**“Software”** means computer software which is integrated or necessary to the operation or functionality of Equipment.

**“Supporting Obligations”** means any “supporting obligations,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Trademark License”** means any written agreement granting any right to use any Trademark or Trademark registration now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

**“Trademarks”** means all of the following property now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (a) all trademarks, tradenames, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof and (b) reissues, extensions or renewals thereof.

**“UCC”** means the Uniform Commercial Code as the same may, from time to time, be in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Secured Party’s Lien on any Collateral is governed by the Uniform Commercial Code as enacted and in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein, terms that are defined in the UCC and used herein shall have the meanings given to them in the UCC.

**Exhibit B**

**See attached list**

Patent portfolio

Intellectual Property (registrations and applications)						
Borrower that is Owner of IP	Family	Name/Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/Publication or Application Number	Filing Date	Estimated Expiration Date
KineMed, Inc.	5006	Compositions and methods of treatment using modulators of motoneuron diseases	Japanese patent issued	2008-549603	1/5/2008	1/5/2028
KineMed, Inc.	5006	See above	US patent issued	11/650,020 8883847	1/5/2007	1/5/2027
KineMed, Inc.	5006-01	Compositions and methods of treatment using modulators of motoneuron diseases	US patent pending	12/994,098	5/21/2008	5/21/2028
KineMed, Inc.	5006-01	See above	Australia patent pending	2009248971	5/21/2009	5/21/2029
KineMed, Inc.	5006-01	See above	Canada patent pending	2725138	5/21/2009	5/21/2029
KineMed, Inc.	5006-01	See above	Europe patent pending	9751593.6	5/21/2009	5/21/2029
KineMed, Inc.	5013	Chemical modification of Apo lipoprotein mimetic peptides for production of therapeutic agents	US patent pending	14/114386	4/30/2012	4/30/2032
KineMed, Inc.	5014	Kinetic biomarkers for Parkinson's disease	US patent pending	14/216,129 2014/0274785 A1	3/17/2014	3/17/2034
KineMed, Inc.	5014	See above	International patent pending	PCT/US2014-030359	3/17/2014	3/17/2034
KineMed, Inc.	5015	The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties	US Provisional	62/031705	7/31/2014	7/31/2035
KineMed, Inc.	5016	Prognostic, Predictive and Pharmacodynamic Kinetic Biomarkers for Neurodegeneration	US Provisional	62/051,884	9/17/2014	9/17/2035



Trademarks					
Borrower that is Owner of IP	Name	Serial Number	Registration Number	Registration Date	
KineMed, Inc.	KINEMED	78321814	3230475	4/17/2007	
KineMed, Inc.	KINEMED	78321792	3230474	4/17/2007	
KineMed, Inc.	KINEMED	78321776	3395688	3/11/2008	
KineMed, Inc.	AQUATAG	78202604	3291448	9/11/2007	
KineMed, Inc.	KINEMARKER	78202582	3280370	8/14/2007	
KineMed, Inc.	KINEMED	78202557	3234122	4/24/2007	

**INBOUND LICENSE #1**

Name and Date of License Agreement: Regents of the University of California  
 Borrower that is Licensee: CineMed, Inc.  
 Name and address of Licensor: Office of Technology Licensing, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620

Name / Identifier of IP		Family #	Type of IP (e.g., patent, TM, ®, mask work)	Registration/ Publication or Application Number		Estimated Expiration Date
				Registration/ Publication or Application Number	Filing Date	
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo		20029	US Issued Patent	5,910,403	5/15/1997	5/15/2017
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo		20029	US Issued Patent	6,010,846	5/8/1998	5/15/2017
Methods For Screening Cellular Proliferation Using Isotope Labels		20029	US Issued Patent	6,461,806	11/15/1999	5/15/2017
Methods For Screening Cellular Proliferation Using Isotope Labels		20029	US Issued Patent	6,808,875	5/24/2002	3/31/2018
Isotopically Labelled DNA		20029	US Issued Patent	7,022,834	9/16/2004	10/18/2017
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo		20029	Australia Issued Patent	737119	5/8/1998	5/8/2018
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo		20029	EP Issued Patent validated in Austria, Belgium, Switzerland, Germany, Denmark, France, Great Britain, Italy, Luxembourg, and Netherlands	980441	5/8/1998	5/8/2018
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo		20029	Canada Issued Patent	2287781	5/8/1998	5/8/2018

Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo	20029	Japan Issued Patent	4510942	5/8/1998	5/8/2018
Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo	20029	Hong Kong Issued Patent	1026004	5/8/1998	5/8/2018
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	US Issued Patent	7,001,587	10/23/2002	4/26/2023
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	US Issued Patent	7,307,059	10/12/2004	1/24/2023
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	US Issued Patent	7,410,633	9/22/2005	7/12/2023
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	Australia Issued Patent	2002365268	10/23/2002	10/23/2022
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	Canada Issued Patent	2464474	10/23/2002	10/23/2022
Measurement Of Protein Synthesis Rates In Humans And Experimental Systems By Use Of Isotopically Labeled Water	20030	EP Issued Patent validated in Great Britain, France, Denmark, Luxembourg, Netherlands, Ireland, Austria, Sweden, Germany, Switzerland, and Belgium	1437966	10/23/2002	10/23/2022
Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	US Issued Patent	7,449,171	2/12/2003	7/31/2024

Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	US Issued Patent	8,084,016	7/15/2008	7/31/2024
Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	Taiwan Issued Patent	1263677	2/12/2003	2/12/2023
Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	Australia Issued Patent	2003217385	2/12/2003	2/12/2023
Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	EP Issued Patent validated in Switzerland, Germany, France, and Great Britain	1483399	2/12/2003	2/12/2023
Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products	20035	Canada Pending Patent Application	2475924	2/12/2003	2/12/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	US Issued Patent	8,129,355	8/3/2009	7/25/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	US Issued Patent	8,481,478	3/1/2012	7/25/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	US Issued Patent	8,969,287	6/19/2013	7/25/2023

Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	US Pending Patent Application	14/605,900	1/26/2015	7/2/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	Australia Issued Patent	2003256819	7/25/2003	7/25/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	Canada Issued Patent	2494715	7/23/2003	7/23/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	Japan Issued Patent	4804753	7/25/2003	7/25/2023
Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organome Using Mass Spectrometry	20038	Singapore Issued Patent	109854	7/25/2003	7/25/2023
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	US Issued Patent	7,255,850	9/15/2003	9/15/2023
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	US Issued Patent	8,021,644	8/3/2007	8/12/2024
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	Australia Issued Patent	2003267283	9/15/2003	9/15/2023
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	Canada Issued Patent	2498378	9/15/2003	9/15/2023
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	Japan Issued Patent	4610337	9/15/2003	9/15/2023

Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	EP Issued Patent validated in Austria, Belgium, Switzerland, Germany, Denmark, France, Great Britain, Ireland, Luxembourg, Netherlands, and Sweden	1546373	9/15/2003	9/15/2023
Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis	20039	Hong Kong Issued Patent	1079822	12/23/2005	12/23/2025
Methods For Determining The Metabolism Of Sugars And Fats In An Individual	20052	US Issued Patent	7,504,233	11/4/2003	5/17/2025
Methods For Identifying The Effect Of A Drug Agent On The Metabolism Of Sugars And Fats In An Individual	20052	US Issued Patent	7,910,323	3/12/2009	11/4/2023
Deuterated Glucose Or Fat Tolerance Tests For High-Throughput Measurement Of The Metabolism Of Sugars Or Fatty Acids In The Body	20052	Australia Issued Patent	2003291731	11/4/2003	11/4/2023
Deuterated Glucose Or Fat Tolerance Tests For High-Throughput Measurement Of The Metabolism Of Sugars Or Fatty Acids In The Body	20052	Canada Issued Patent	2504313	11/4/2003	11/4/2023
Deuterated Glucose Or Fat Tolerance Tests For High-Throughput Measurement Of The Metabolism Of Sugars Or Fatty Acids In The Body	20052	Japan Issued Patent	2006505777	11/4/2003	11/4/2023
Methods For Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo Through A Single Protocol	20059	US Issued Patent	7,262,020	6/17/2004	6/17/2024
Methods For Detecting, Progressing, Or Monitoring A Disorder By Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo	20059	US Issued Patent	7,357,913	5/11/2006	7/6/2024
Methods For Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo Through A Single Protocol	20059	Singapore Issued Patent	118711	6/29/2004	6/29/2024

Methods For Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo Through A Single Protocol	20059	Canada Issued Patent	2530789		6/29/2004	6/29/2024
Methods For Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo Through A Single Protocol	20059	EP Issued Patent validated in Belgium, Switzerland, Germany, Denmark, France, and Great Britain	1663319		6/29/2004	6/29/2024
Methods For Comparing Relative Flux Rates Of Two Or More Biological Molecules In Vivo Through A Single Protocol	20059	Canada Pending Patent Application	2840691		6/29/2004	6/29/2024
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity	20067	US Issued Patent	8,005,623		2/22/2005	11/26/2027
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity in Adipose pathway	20067.1	US Issued Patent	8,401,800		8/22/2011	6/17/2024
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity in mitochondrial pathway	20067.01	US Issued Patent	2013/781505 8,849,581		2/28/2013	6/17/2024
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity	20067.02	US Pending Patent Application	2014/0295484		3/7/2014	6/17/2024
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity in lipogenesis pathway	20067.03	US Issued Patent	9043159		5/26/2015	6/17/2024
Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity	20067.04	US Patent Allowed	2014/0295485		3/7/2014	6/17/2024

Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity In Solid Or Liquid Tumors	20067.05	US Issued Patent	9037417		3/7/2014	6/17/2024
Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems	20076	US Issued Patent	8,663,602		2/18/2011	11/23/2024
Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems	20076	Singapore Issued Patent	122483		11/24/2004	11/24/2024
Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems	20076	US Pending Patent Application	2014/0162900		1/29/2014	11/23/2024
Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems	20076	Canada Pending Patent Application	2546868		11/24/2004	11/24/2024
Methods for measuring cholesterol metabolism and transport	20078	US Pending Patent Application	2006/0251576		5/2/2006	5/2/2026
Monitoring Two Dimensions Of Diabetes Pathogenesis	20079	US Issued Patent	8,741,589		6/12/2006	5/17/2025
Diagnosis And Prognosis Of Diabetes	20079	EP Issued Patent validated in Switzerland, Germany, France, Great Britain, and Italy	1907018		6/12/2006	6/12/2026



Method For Replacing Biomarkers Of Protein Kinetics From Tissue Samples By Biomarkers Of Protein Kinetics From Body Fluids After Isotopic Labeling In Vivo	20099	US Pending Patent Application	2014/0273044	3/13/2014	3/13/2034
Method For Replacing Biomarkers Of Protein Kinetics From Tissue Samples By Biomarkers Of Protein Kinetics From Body Fluids After Isotopic Labeling In Vivo	20099	PCT Pending Patent Application	PCT/US2014/028931	3/14/2014	NA
Methods For Determining Total Body Skeletal Muscle Mass Using A Correction Factor	20629	PCT Pending Patent Application	PCT/US2014/042186	6/12/2014	NA
Methods For Determining Total Body Skeletal Muscle Mass	20630	US Pending Patent Application	14/363,779	6/6/2014	12/6/2032
Methods For Determining Total Body Skeletal Muscle Mass	20630	Canada Pending Patent Application	2858368	12/6/2012	12/6/2032
Methods For Determining Total Body Skeletal Muscle Mass	20630	EP Pending Patent Application	2788772	12/6/2012	12/6/2032
Methods For Determining Total Body Skeletal Muscle Mass	20630	Japan Pending Patent Application	2014546045	12/6/2012	12/6/2032
Method For Measuring In Vivo Synthesis Of Biopolymers	NA	US Issued Patent	5,338,686	4/29/1992	4/29/2012

INBOUND LICENSE # 2			
Name and Date of License Agreement:	Know-How Transfer Agreement effective 7/1/2013		
Borrower that is Licensee:	KineMed, Inc.		
Name and address of Licensor:	Emory University, Office of Technology Transfer, North Decatur Bldg., Suite 130, 1784 N. Decatur Rd, Atlanta, Georgia 20322		
Describe Licensed Intellectual Property For This License			
Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/ Publication or Application Number	Filing Date/Expiration
Moscapine cancer data package	Data	NA	7/1/2020

INBOUND LICENSE # 3			
Name and Date of License Agreement:	Etiocolandione and Etiocolanolone compound license dated 9/20/2004		
Borrower that is Licensee:	KineMed, Inc.		
Name and address of Licensor:	SuperGen, Inc., 4140 Dublin Blvd, Suite 200, Dublin CA 94568-7757		
Expiration Date of License	Upon invalidation of patent		
Describe Licensed Intellectual Property For This License			
Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/ Publication or Application Number	Filing Date/Expiration
Etiocolandione and Etiocolanolone compound license	license to commercialize compound	NA	NA

INBOUND LICENSE # 4			
Name and Date of License Agreement:	Public Health Service Patent License Agreement L-035-2012/0 for use in Cardiovascular effective 1/3/2012		
Borrower that is Licensee:	KineMed, Inc.		
Name and address of Licensor:	Public Health Service, Chief of Monitoring & Enforcement Branch, Office of Technology Transfer, National Institutes of Health, 6011 Executive Blvd, Suite 325, Rockville, MD, 20852-3804		
Describe Licensed Intellectual Property For This License			
Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/ Publication or Application Number	Filing Date/Expiration
Commercialization of the 5A peptide for use in treating cardiovascular disease	license support by patent	See below	

PATENT OR PATENT APPLICATION(S)

Patent(s) or Patent Application(s):

- I. United States Provisional Patent Application No. 60/619,392, filed October 15, 2004, entitled "Assay System and Composition of Multi-Domain Amphipathic Helical Peptides for the Treatment of Atherosclerosis" (HHS Ref. No. E-114-2004/0-US-01). Status: Converted PCT.
- II. PCT Application No. US2005/036933, filed October 14, 2005, entitled, "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use" (HHS Ref. No. E-114-2004/0-PCT-02). Status: Expired.
- III. Australian Patent Application Serial No. 2005295640, filed October 14, 2005, entitled "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use", (HHS Ref. No. E-114-2004/0-AU-03). Status: Allowed.
- IV. Canadian Patent Application Serial No. 2584048, filed October 14, 2005, entitled "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use" (HHS Ref. No. E-114-2004/0-CA-04). Status: Pending.
- V. European Patent Application Serial No. 05815961.7, filed October 14, 2005, entitled "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use" (HHS Ref. No. E-114-2004/0-EP-05). Status: Issued on May 26, 2010 as Patent Number 1812474.
- VI. Swiss Patent Serial No. 1812474, filed October 14, 2005, entitled "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use" (HHS Ref. No. E-114-2004/0-CH-11). Issued on May 26, 2010 as Patent Number 1812474.
- VII. German Patent Serial No. 1812474, filed October 14, 2005, entitled "Multi-Domain Amphipathic Helical Peptides and Methods of Their Use" (HHS Ref. No. E-114-2004/0-DE-12). Issued on May 26, 2010 as

INBOUND LICENSE # 5			
Name and Date of License Agreement:	License Agreement (SUN11031) (synthetic ghrelin) effective February 2016		
Borrower that is Licensee:	KineMed, Inc.		
Name and address of Licensor:	BioPharma Forest, Inc. 4-9-14 Azamino, Aoba-ku-Yokohama-city, Kanagawa 225-0011, Japan		
Describe Licensed Intellectual Property For This License			
Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/ Publication or Application Number	Filing Date/Expiration
See attached list of patents			

Details of the patents/patent applications\* and intellectual property for the Compound and Compound Rights

1. WO01/07475

AU784035, AU2006201580  
BR PI0012688-8\*, BR1220140122209\*  
CA2380058, CA2696819  
CN810440.9, CN200910141231.1\*  
EP1197496 (AU, BE, CH, LI, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)  
EP1795598 (AU, BE, CH, LI, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)  
EP2119785 (DE, ES, FR, GB, IT)  
IL147652, IL198562  
JP3471780, JP4227857  
KR827973  
US7385026, US8227570, US8524871, US12/728495\*, US13/494673\*

2. WO2004/096260

EP1632244 (DE, ES, FR, GB, IT)  
JP4467518  
US10/554875\*

3. WO03/084983

AU2003236080  
BR PI0306644-4\*  
CA2472235  
CN3801905.1  
EP1493747 (AU, CH, LI, DE, ES, FR, GB, HU, IE, IT)  
IL162780  
JP4276462  
KR1036524  
US7138489

4. WO2003/097083

AU2003235401  
BR PI0306685-1\*  
CA2471879  
CN3802830.1  
EP03752939.3\*  
IL162796  
JP5000848  
US8440628, US8518893

5. WO2006/022301

AU2005275779  
BR PI0514408-6\*  
CA2576473

CN200580028594.6  
EP05774895.6\*  
IL181348  
JP4951344  
KR1149454  
US8969298

6. WO2006/090767

AU2006216218  
BR PI0607475-8\*  
CA2598864\*  
CN200680005911.7  
EP1862173 (DE, FR, GB)  
IL184931  
JP4843827  
KR1295104  
RU2403058  
US7803768

7. WO2011/087102

EP11732972.2\*  
JP2011-550026\*, 2015-155787\*  
US9078868

8. WO2012/117592

AU2011361144\*  
BR1120130218592\*  
JP2013-502135\*  
US14/002570\*

9. WO2014/065341

AU2013335678\*  
BR1120150091075\*  
CA2889499\*  
CN201380066625.1\*  
EP13848825.9\*  
IN4172/DELNP/2015\*  
JP2014-543332\*  
KR2015-7010085\*  
RU2015119472\*  
US14/437459\*

All "Know-How" related thereto.